Pharmaceutical News and Articles

Birth Control Pill Increases Risk Of Asthma Attacks In Young Women

Young women taking the Pill might have an increased risk of asthma attacks, a new study says.Taking the progesterone-only form of the contraceptive pill can inc

FDA Approves At-Home Cervical Cancer Test for Women Ages 25 to 65

MONDAY, May 12, 2025 Women now have a new way to check their risk for cervical cancer from the comfort of their own home.The U.S. Food and Drug Administration (

U.S. Illicit Opioid Use Could Be 20 Times Higher Than Previously Estimated

MONDAY, May 12, 2025 More Americans use illicit opioids like fentanyl than previously estimated, undercutting perceived progress in confronting the U.S. opioid

Pregnancy Health Problems Increase Kids' Blood Pressure

Children have an increased risk of high blood pressure if their moms suffered from health problems during pregnancy, a new study says.Children had higher blood

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

Aldeyra Therapeutics, Inc. (Nasdaq ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-

Boehringer Ingelheim Starts Phase II Study of BI 1584862, Potential First-in-Class Oral Compound as a Treatment for Geographic Atrophy​

Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a poten

GLISTEN Phase III Trial Results Show Linerixibat Significantly Improves Cholestatic Pruritus in Primary Biliary Cholangitis

GSK plc (LSE NYSE GSK) today announced positive results from the GLISTEN phase III trial evaluating linerixibat, an investigational targeted inhibitor of the il

Icotrokinra Results Show Significant Skin Clearance in Patients with Difficult-to-Treat Scalp and Genital Psoriasis

SPRING HOUSE, Pa. (May 9, 2025) Johnson Johnson (NYSE JNJ) today announced new data from the Phase 3 ICONIC-TOTALa study investigating icotrokinra (JNJ-2113), t

Zepbound (tirzepatide) Showed Superior Weight Loss Over Wegovy (semaglutide) in Complete SURMOUNT-5 Results Published in The New England Journal of Medicine

Eli Lilly and Company (NYSE LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of Z

FDA Approves Avmapki Fakzynja Co-Pack (avutometinib capsules/defactinib tablets) for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer